Cushing's syndrome and Acromegaly Treatment Market – Current Scenario and Future

Posted by Rohini Chaudhari on June 26th, 2019

Global Cushing’s syndrome and Acromegaly Treatment Market: Overview 

Cushing’s syndrome is cause by increased production of corticosteroid hormones often resulting in high blood pressure and obesity. On the other hand, Acromegaly is a chronic disorder cause due to excess production of growth hormones. The global Cushing’s syndrome and Acromegaly treatment market is anticipated to display promising growth during the forecast period owing to the advancements in the healthcare industry.

Report Overview @ https://www.transparencymarketresearch.com/cushings-syndrome-and-acromegaly-treatment-market.html

Global Cushing’s Syndrome and Acromegaly Treatment Market: Notable Developments 

Below are a few notable developments in the global Cushing’s syndrome and Acromegaly treatment market:

  • Development of Pegvisomant Therapy has proved to be a major breakthrough in the global Cushing’s syndrome and Acromegaly treatment market. Pegvisomant is a growth hormone receptor antagonist that functions by preventing the endogenous growth hormone from binding to its receptor. It has proven to considerably reduce the concentration of insulin-level growth factor 1, responsible for the spread of the disease. Development of this therapy has helped the Cushing’s syndrome and Acromegaly treatment market to expand its global footprints.
  • Cabergoline, an oral agent has proven to be useful for the treatment of Cushing’s disesase. It is a dopamine receptor antagonist popularly used for the treatment of prolactinomas. This effectively reduces the level of urinary free cortisol and shrinks the pituitary adenoma to a level where it cannot be detected in an MRI, thereby aiding an efficient treatment of the disease. This has presented numerous growth opportunities for the global Cushing’s syndrome and Acromegaly treatment market.

Prominent players in the global Cushing’s syndrome and Acromegaly treatment market comprise Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Corcept Therapeutics, Ipsen Biopharmaceuticals, and HRA Pharma.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=65378

Global Cushing’s Syndrome and Acromegaly Treatment Market: Key Growth Dynamics 

Development of new drug therapies with minimal or no side effects has highly contributed to the expansion of global Cushing’s syndrome and Acromegaly treatment market. Moreover, an increasing support from governments for the treatment Cushing’s syndrome and Acromegaly is anticipated to boost the market’s growth. Governments support the treatment of these diseases by spreading awareness and through funding

Additionally, there has been an increase in the disposable incomes in the emerging countries leading to a greater adoption of new treatments, thereby expediting the growth of global Cushing’s syndrome and Acromegaly treatment market. Along with this, rising prevalence of Cushing’s syndrome and Acromegaly has also facilitated the industry’s growth.

 

Like it? Share it!


Rohini Chaudhari

About the Author

Rohini Chaudhari
Joined: June 12th, 2019
Articles Posted: 205

More by this author